Coughs that linger after a cold or sinus problem cause constant disruption in the home, school, and workplace. Often, these dry, nonproductive coughs become increasingly troublesome although other symptoms ?fever, congestion, and fatigue ?resolved days or weeks ago. This stubborn cough persists for weeks, and plagues its victim and the victim's family night and day. The diagnosis might be a common, but overlooked cause of lingering cough: atypical pneumonia caused by mycoplasma. Mycoplasma ? pleomorphic bacteria that lack a cell wall ?are the smallest and simplest self-replicating organisms known to humans. They probably evolved from gram-positive, walled eubacteria by degenerative evolution. Smaller than amoebas, these 0.1-micrometer organisms grow and reproduce slowly and require no oxygen or host cell. They also change shapes asymmetrically, appearing as long, thin filaments, tiny spheres, or branches. Scientists have identified more than 100 mycoplasma species. Fifteen species are known to live in humans, most as normal symbiotic flora. Mycoplasma pneumoniae, previously called "walking pneumonia," is pathogenic in humans. Mycoplasma pneumoniae glides freely and uses its specialized filamentous tips to burrow between cilia within the respiratory epithelium, causing the respiratory epithelial cells to slough. It also produces hydrogen peroxide, which causes initial cell disruption in the respiratory tract and damages erythrocyte membranes. Researchers have determined that more than 40% of infants younger than 1 year old have had a mycoplasma infection. By age 5, approximately 65% of children have been infected. Nearly all adults have been infected at least once, often repeatedly. Mycoplasma pneumonia usually affects people younger than 40 years of age. The highest incidence is found in the 5- to 9-year age group. The risk of contracting mycoplasma pneumonia is greatest for people who live or work in crowded areas, such as daycare facilities, schools, homeless shelters, long-term care units, and military and prison environments. However, many people who develop mycoplasma infections have no identifiable risk factor. Most mycoplasma infections cause mild to moderate clinical symptoms, but the infection incubates over 3 weeks and can last weeks without treatment. This infection cannot be diagnosed based on symptoms alone; laboratory testing is essential. Infection can also cause ear infections, sinus infections, bronchitis, croup, severe sore throats, infectious asthma, and 1 type of the common cold. When mycoplasma infects children, about 25% of them develop nausea, vomiting, or diarrhea.
It is probable that mycoplasma pneumonia is most common in crowded areas because:
A. they evolved from eubacteria primarily infect children.
B. they lack a cell wall, they glide freely, and they produce hydrogen peroxide.
C. they require no oxygen or host cell, they are very small, and they are able to burrow between cilia.
D. they have no identifiable risk factor and incubate over 3 weeks.
Coughs that linger after a cold or sinus problem cause constant disruption in the home, school, and workplace. Often, these dry, nonproductive coughs become increasingly troublesome although other symptoms ?fever, congestion, and fatigue ?resolved days or weeks ago. This stubborn cough persists for weeks, and plagues its victim and the victim's family night and day. The diagnosis might be a common, but overlooked cause of lingering cough: atypical pneumonia caused by mycoplasma. Mycoplasma ? pleomorphic bacteria that lack a cell wall ?are the smallest and simplest self-replicating organisms known to humans. They probably evolved from gram-positive, walled eubacteria by degenerative evolution. Smaller than amoebas, these 0.1-micrometer organisms grow and reproduce slowly and require no oxygen or host cell. They also change shapes asymmetrically, appearing as long, thin filaments, tiny spheres, or branches. Scientists have identified more than 100 mycoplasma species. Fifteen species are known to live in humans, most as normal symbiotic flora. Mycoplasma pneumoniae, previously called "walking pneumonia," is pathogenic in humans. Mycoplasma pneumoniae glides freely and uses its specialized filamentous tips to burrow between cilia within the respiratory epithelium, causing the respiratory epithelial cells to slough. It also produces hydrogen peroxide, which causes initial cell disruption in the respiratory tract and damages erythrocyte membranes. Researchers have determined that more than 40% of infants younger than 1 year old have had a mycoplasma infection. By age 5, approximately 65% of children have been infected. Nearly all adults have been infected at least once, often repeatedly. Mycoplasma pneumonia usually affects people younger than 40 years of age. The highest incidence is found in the 5- to 9-year age group. The risk of contracting mycoplasma pneumonia is greatest for people who live or work in crowded areas, such as daycare facilities, schools, homeless shelters, long-term care units, and military and prison environments. However, many people who develop mycoplasma infections have no identifiable risk factor. Most mycoplasma infections cause mild to moderate clinical symptoms, but the infection incubates over 3 weeks and can last weeks without treatment. This infection cannot be diagnosed based on symptoms alone; laboratory testing is essential. Infection can also cause ear infections, sinus infections, bronchitis, croup, severe sore throats, infectious asthma, and 1 type of the common cold. When mycoplasma infects children, about 25% of them develop nausea, vomiting, or diarrhea.
The primary purpose of this passage is:
A. to give background information about mycoplasma
B. to describe the dangers of mycoplasma
C. to provide details on how mycoplasma primarily infects children
D. to trace the cause of the common cold
Coughs that linger after a cold or sinus problem cause constant disruption in the home, school, and workplace. Often, these dry, nonproductive coughs become increasingly troublesome although other symptoms ?fever, congestion, and fatigue ?resolved days or weeks ago. This stubborn cough persists for weeks, and plagues its victim and the victim's family night and day. The diagnosis might be a common, but overlooked cause of lingering cough: atypical pneumonia caused by mycoplasma. Mycoplasma ? pleomorphic bacteria that lack a cell wall ?are the smallest and simplest self-replicating organisms known to humans. They probably evolved from gram-positive, walled eubacteria by degenerative evolution. Smaller than amoebas, these 0.1-micrometer organisms grow and reproduce slowly and require no oxygen or host cell. They also change shapes asymmetrically, appearing as long, thin filaments, tiny spheres, or branches. Scientists have identified more than 100 mycoplasma species. Fifteen species are known to live in humans, most as normal symbiotic flora. Mycoplasma pneumoniae, previously called "walking pneumonia," is pathogenic in humans. Mycoplasma pneumoniae glides freely and uses its specialized filamentous tips to burrow between cilia within the respiratory epithelium, causing the respiratory epithelial cells to slough. It also produces hydrogen peroxide, which causes initial cell disruption in the respiratory tract and damages erythrocyte membranes. Researchers have determined that more than 40% of infants younger than 1 year old have had a mycoplasma infection. By age 5, approximately 65% of children have been infected. Nearly all adults have been infected at least once, often repeatedly. Mycoplasma pneumonia usually affects people younger than 40 years of age. The highest incidence is found in the 5- to 9-year age group. The risk of contracting mycoplasma pneumonia is greatest for people who live or work in crowded areas, such as daycare facilities, schools, homeless shelters, long-term care units, and military and prison environments. However, many people who develop mycoplasma infections have no identifiable risk factor. Most mycoplasma infections cause mild to moderate clinical symptoms, but the infection incubates over 3 weeks and can last weeks without treatment. This infection cannot be diagnosed based on symptoms alone; laboratory testing is essential. Infection can also cause ear infections, sinus infections, bronchitis, croup, severe sore throats, infectious asthma, and 1 type of the common cold. When mycoplasma infects children, about 25% of them develop nausea, vomiting, or diarrhea.
A diagnosis of mycoplasma may be suspected in cases in which:
A. fever, congestion, and fatigue were never present
B. fever, congestion, and fatigue were present initially, but then went away
C. fever, congestion, and fatigue remain constant during the cough
D. fever, congestion, and fatigue go away with the cough
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
The side note, "often mispronounced purposefully or accidentally as `old timers' disease," best functions in what way in the first paragraph?
A. Give a relatable anecdote for the reader to begin a description of a serious topic.
B. Make a joke about a serious topic.
C. Provide background details about Alzheimer's disease.
D. Teach the reader a nickname of the disease.
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
Acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists can do which of the following to help AD patients?
A. monitor progression
B. decrease disruptive behavior
C. stop disease progression
D. delay cognitive function
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
The final paragraph primarily serves to: A. Detail the transition from early stage Alzheimer's to the severe stages of the disease.
B. Outline the different treatment options available to patients.
C. Explain how patients decide which treatment to pursue.
D. Describe how health care professionals decide when to terminate treatment.
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
The author's attitude toward Alzheimer's disease is best summarized by which of the following?
A. Pessimistic about the future prospects surrounding the disease and potential treatments.
B. Accepting of the disease's inevitabilities and forthright about the extent of different treatments' effectiveness.
C. Critical of the treatment methods utilized by health care professionals.
D. Apathetic toward developing new treatments for the disease.
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
A patient with Alzheimer's might show language difficulties by describing a computer as:
A. a desktop
B. a laptop
C. a computer
D. an information-giver
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
In paragraph 2, "harbinger" most nearly means?
A. token
B. precursor
C. messenger
D. problem
For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.
Which of the following is NOT something pharmacists can provide information about?
A. myths about AD
B. truths about AD
C. cures for AD
D. treatments for AD
Nowadays, the certification exams become more and more important and required by more and more enterprises when applying for a job. But how to prepare for the exam effectively? How to prepare for the exam in a short time with less efforts? How to get a ideal result and how to find the most reliable resources? Here on Vcedump.com, you will find all the answers. Vcedump.com provide not only Admission Tests exam questions, answers and explanations but also complete assistance on your exam preparation and certification application. If you are confused on your PCAT exam preparations and Admission Tests certification application, do not hesitate to visit our Vcedump.com to find your solutions here.